BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...co-founder Renato Skerlj to CSO, a newly created position, from SVP of R&D. Immuno-oncology play Sensei Biotherapeutics Inc....
...Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx Ltd. Summit Therapeutics plc X4 Pharmaceuticals Inc. Sensei Biotherapeutics Inc....
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...University College London Cancer Institute and a senior cancer research fellow at Cancer Research UK. Sensei Biotherapeutics Inc....
BioCentury | Aug 21, 2018
Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

...will become executive chairman. He is succeeded by President and CMO Vicken Karageozian. Immuno-oncology company Sensei Biotherapeutics Inc....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...was CBO at Eidos Therapeutics Inc. (San Francisco, Calif.). Immuno-oncology company Sensei Biotherapeutics Inc. (Gaithersburg, Md.), formerly Panacea Pharmaceuticals...
BioCentury | Aug 3, 2017
Strategy

FDA's phage philosophy

...phage cocktails for P. aeruginosa infections in burn victims in Phase I/II trials in Europe. Panacea Pharmaceuticals...
...of Allergy and Infectious Diseases (NIAID), Bethesda, Md. National Institutes of Health (NIH), Bethesda, Md. Panacea Pharmaceuticals...
...Spring, Md. Targets ASPH (HAAH) - aspartate β-hydroxylase Mark Zipkin, Staff Writer AmpliPhi Biosciences Corp. National Institutes of Health Panacea Pharmaceuticals...
BioCentury | Feb 1, 2017
Clinical News

PAN-301-1: Ph I started

...an open-label, dose-escalation, U.S. Phase I trial to evaluate intradermal PAN-301-1 in about 18 patients. Panacea Pharmaceuticals...
...cancer Endpoint: Recommended Phase II dose, safety and immunogenicity Status: Phase I started Milestone: NA Alex Himes Panacea Pharmaceuticals...
BioCentury | Dec 14, 2015
Financial News

Panacea Pharmaceuticals completes venture financing

Panacea Pharmaceuticals Inc. , Gaithersburg, Md. Business: Cancer, Neurology Date completed: 2015-12-08 Type: Venture financing Raised: $15 million Note: The company has also secured an additional $2 million optional financing commitment in the round. WIR Staff...
BioCentury | Nov 19, 2007
Company News

Panacea Pharmaceuticals sales and marketing update

...cancer diagnostic, which measures the level of human aspartyl (asparaginyl) beta- hydroxylase (HAAH) in blood. Panacea Pharmaceuticals...
BioCentury | Oct 22, 2007
Company News

Panacea Pharmaceuticals sales and marketing update

...which measures levels of the cancer marker human aspartyl (asparaginyl) beta-hydroxylase (HAAH) in blood. Panacea Pharmaceuticals...
BioCentury | Jul 23, 2007
Company News

Panacea Pharmaceuticals management update

Panacea Pharmaceuticals Inc. , Gaithersburg, Md. Business: Cancer, Neurology Hired: Steven Fuller as VP of product development, formerly VP of product and process development at Nabi Biopharmaceuticals WIR Staff cancer Neurology...
Items per page:
1 - 10 of 49
BioCentury | Jun 20, 2020
Management Tracks

Nurix bolsters leadership; plus Lynch named Xilio chairman, Edgewise, BioXCel, Catabasis, Catalyst and more

...co-founder Renato Skerlj to CSO, a newly created position, from SVP of R&D. Immuno-oncology play Sensei Biotherapeutics Inc....
...Inc. Edgewise Therapeutics BioXcel Therapeutics Inc. Catabasis Pharmaceuticals Inc. Catalyst BioMedica Kronos Bio Inc. Canbridge Pharmaceuticals Inc. Healx Ltd. Summit Therapeutics plc X4 Pharmaceuticals Inc. Sensei Biotherapeutics Inc....
BioCentury | Mar 19, 2020
Management Tracks

Leng will become NICE chief executive; plus BMS, Sofinnova, Medicxi, PTC, Orchard and more

...University College London Cancer Institute and a senior cancer research fellow at Cancer Research UK. Sensei Biotherapeutics Inc....
BioCentury | Aug 21, 2018
Company News

Management tracks: HBP parts ways with Executive Director Chris Ebell

...will become executive chairman. He is succeeded by President and CMO Vicken Karageozian. Immuno-oncology company Sensei Biotherapeutics Inc....
BioCentury | May 16, 2018
Company News

Management tracks: Novartis, Aileron

...was CBO at Eidos Therapeutics Inc. (San Francisco, Calif.). Immuno-oncology company Sensei Biotherapeutics Inc. (Gaithersburg, Md.), formerly Panacea Pharmaceuticals...
BioCentury | Aug 3, 2017
Strategy

FDA's phage philosophy

...phage cocktails for P. aeruginosa infections in burn victims in Phase I/II trials in Europe. Panacea Pharmaceuticals...
...of Allergy and Infectious Diseases (NIAID), Bethesda, Md. National Institutes of Health (NIH), Bethesda, Md. Panacea Pharmaceuticals...
...Spring, Md. Targets ASPH (HAAH) - aspartate β-hydroxylase Mark Zipkin, Staff Writer AmpliPhi Biosciences Corp. National Institutes of Health Panacea Pharmaceuticals...
BioCentury | Feb 1, 2017
Clinical News

PAN-301-1: Ph I started

...an open-label, dose-escalation, U.S. Phase I trial to evaluate intradermal PAN-301-1 in about 18 patients. Panacea Pharmaceuticals...
...cancer Endpoint: Recommended Phase II dose, safety and immunogenicity Status: Phase I started Milestone: NA Alex Himes Panacea Pharmaceuticals...
BioCentury | Dec 14, 2015
Financial News

Panacea Pharmaceuticals completes venture financing

Panacea Pharmaceuticals Inc. , Gaithersburg, Md. Business: Cancer, Neurology Date completed: 2015-12-08 Type: Venture financing Raised: $15 million Note: The company has also secured an additional $2 million optional financing commitment in the round. WIR Staff...
BioCentury | Nov 19, 2007
Company News

Panacea Pharmaceuticals sales and marketing update

...cancer diagnostic, which measures the level of human aspartyl (asparaginyl) beta- hydroxylase (HAAH) in blood. Panacea Pharmaceuticals...
BioCentury | Oct 22, 2007
Company News

Panacea Pharmaceuticals sales and marketing update

...which measures levels of the cancer marker human aspartyl (asparaginyl) beta-hydroxylase (HAAH) in blood. Panacea Pharmaceuticals...
BioCentury | Jul 23, 2007
Company News

Panacea Pharmaceuticals management update

Panacea Pharmaceuticals Inc. , Gaithersburg, Md. Business: Cancer, Neurology Hired: Steven Fuller as VP of product development, formerly VP of product and process development at Nabi Biopharmaceuticals WIR Staff cancer Neurology...
Items per page:
1 - 10 of 49